EULAR® 2024 Insights: Guselkumab Provides Durable Improvements in Pain Among Patients With Psoriatic Arthritis and an Inadequate Response to TNFi: COSMOS Phase 3b Trial

48 views
June 21, 2024
Comments 0
Login to view comments. Click here to Login